260 related articles for article (PubMed ID: 23252566)
1. Triptorelin in the management of prostate cancer.
Ploussard G; Mongiat-Artus P
Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
3. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Merseburger AS; Hupe MC
Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer.
Romero E; Vélez de Mendizabal N; Cendrós JM; Peraire C; Bascompta E; Obach R; Trocóniz IF
J Pharmacol Exp Ther; 2012 Sep; 342(3):788-98. PubMed ID: 22691297
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
8. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
Bolton EM; Lynch T
BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of long-acting gonadotropin-releasing hormone analogue in the treatment for metastatic prostate cancer].
Li NC; Song Y; Jiang HW; Ding Q; Gan WD; Guo HQ; Sun ZY; Hu ZQ; Ye ZQ; Wei Q; Na YQ
Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1653-7. PubMed ID: 19094763
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.
Minkov NK; Zozikov BI; Yaneva Z; Uldry PA
Int Urol Nephrol; 2001; 33(2):379-83. PubMed ID: 12092661
[TBL] [Abstract][Full Text] [Related]
11. Triptorelin embonate (6-month formulation).
Keating GM
Drugs; 2010 Feb; 70(3):347-53. PubMed ID: 20166771
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
13. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
Novara G; Galfano A; Secco S; Ficarra V; Artibani W
Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
[TBL] [Abstract][Full Text] [Related]
14. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
Labrie F; Bélanger A; Luu-The V; Labrie C; Simard J; Cusan L; Gomez J; Candas B
Endocr Rev; 2005 May; 26(3):361-79. PubMed ID: 15867098
[TBL] [Abstract][Full Text] [Related]
17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer.
Teillac P; Heyns CF; Kaisary AV; Bouchot O; Blumberg J
Horm Res; 2004; 62(5):252-8. PubMed ID: 15499224
[TBL] [Abstract][Full Text] [Related]
19. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.
Lundström EA; Rencken RK; van Wyk JH; Coetzee LJ; Bahlmann JC; Reif S; Strasheim EA; Bigalke MC; Pontin AR; Goedhals L; Steyn DG; Heyns CF; Aldera LA; Mackenzie TM; Purcea D; Grosgurin PY; Porchet HC
Clin Drug Investig; 2009; 29(12):757-65. PubMed ID: 19888782
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
